ADSS

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors

Retrieved on: 
Thursday, January 12, 2023
Class Action Lawsuit, Professional Services, Legal, News, ADS, ADSS, Bioline, BioLineRx, SCSP, GPM, Defendant, Suite, Court, Investment, Security (finance), Bank

BioLine investors have until March 6, 2023 to file a lead plaintiff motion.

Key Points: 
  • BioLine investors have until March 6, 2023 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, the Company’s share price fell 33% to close at $1.02 per share on September 19, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

Retrieved on: 
Wednesday, January 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Form, ADS, Park Avenue, NIS, ADSS, Regulation D, Series, Institute of Liver and Biliary Sciences, 3rd Floor, NYSE, The Act, Research, Cancer, Sale, CANF, SEC filing, Prospectus, Exercise, TASE, Security (finance)

In a concurrent private placement, Can-Fite has also agreed to issue and sell 363,637 of its ADS (or ADS equivalents in lieu thereof), at the same purchase price as in the registered direct offering.

Key Points: 
  • In a concurrent private placement, Can-Fite has also agreed to issue and sell 363,637 of its ADS (or ADS equivalents in lieu thereof), at the same purchase price as in the registered direct offering.
  • Each ADS represents three hundred (300) ordinary shares, par value NIS 0.25 per share, of Can-Fite.
  • The offering of the ADSs (or ADS equivalents) to be issued in the registered direct offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors

Retrieved on: 
Wednesday, January 11, 2023
Class Action Lawsuit, Professional Services, Legal, News, ADS, ADSS, Bioline, Law, BioLineRx, Telephone, SCSP, Defendant, Suite, Investment, Security (finance), Bank

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX ) American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX ) American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022, inclusive (the “Class Period”).
  • BioLine investors have until March 6, 2023 to file a lead plaintiff motion.
  • Investors suffering losses on their BioLine investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors

Retrieved on: 
Tuesday, January 10, 2023
Class Action Lawsuit, Professional Services, Legal, News, ADS, Person, ADSS, Bioline, Law, BioLineRx, SCSP, Defendant, Suite, Court, Bank, Security (finance)

BioLine investors have until March 6, 2023 to file a lead plaintiff motion.

Key Points: 
  • BioLine investors have until March 6, 2023 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On this news, the Company’s share price fell 33% to close at $1.02 per share on September 19, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioLineRx Ltd. (BLRX) on Behalf of Investors

Retrieved on: 
Tuesday, January 10, 2023
Class Action Lawsuit, Professional Services, Legal, News, ADS, ADSS, Bioline, American depositary receipt, BioLineRx, Person, SCSP, GPM, Investment, Security (finance)

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX ) investors concerning the Company’s possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, the Company’s share price fell 33% to close at $1.02 per share on September 19, 2022.
  • Whistleblower Notice: Persons with non-public information regarding BioLine should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.

China Southern Airlines Company Limited

Retrieved on: 
Friday, January 13, 2023
Form, ADS, Hong Kong Stock Exchange, ADSS, China Southern Airlines, SSE, Bangladesh Securities and Exchange Commission, NYSE, Eastern Time Zone, Shanghai Stock Exchange, Exchange, Stock exchange, Arizona Stock Exchange, Security (finance)

From and after that date, the ADSs of the Company will no longer be listed and traded on the NYSE.

Key Points: 
  • From and after that date, the ADSs of the Company will no longer be listed and traded on the NYSE.
  • Once the Form 15F is filed, the Company will publish the information required under Rule 12g3-2(b) of the Exchange Act on its website, https://www.csair.com .
  • The Company intends to terminate its ADS program after delisting its ADSs from the NYSE in due course in accordance with the deposit agreement.
  • H Shares of the Company will continue to be traded on the Hong Kong Stock Exchange.

Opera Limited declares special dividend of $0.80 per ADS

Retrieved on: 
Thursday, January 12, 2023
OPRA, ADS, BNY Mellon, ADSS, CFO, IPO, Internet, Sale, Bank, Holding company, Security (finance)

"In light of Opera's strong operating performance through 2022, we are pleased to announce our first dividend since our IPO," said Opera Co-CEO, Mr Lin Song.

Key Points: 
  • "In light of Opera's strong operating performance through 2022, we are pleased to announce our first dividend since our IPO," said Opera Co-CEO, Mr Lin Song.
  • "In addition to a successful core business, Opera has a solid balance sheet and non-core assets held for sale as well as receivables from non-core assets already divested.
  • In combination, we believe this is the right time to reward our shareholders with a dividend."
  • The aggregate payment to be made in connection with this special dividend is approximately $71 million, based on a total of 89,215,121 ADS equivalents outstanding as of December 31, 2022.

Yunji Announces Receipt of Nasdaq Notice

Retrieved on: 
Thursday, January 12, 2023
YJ, Yunji, ADSS, American depositary receipt, Auction

HANGZHOU, China, Jan. 12, 2023 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 11, 2023, indicating that because the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days was below US$1.00 per share, the Company no longer meets the Nasdaq minimum bid price requirement, set forth in Nasdaq Listing Rule 5450(a)(1).

Key Points: 
  • HANGZHOU, China, Jan. 12, 2023 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 11, 2023, indicating that because the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days was below US$1.00 per share, the Company no longer meets the Nasdaq minimum bid price requirement, set forth in Nasdaq Listing Rule 5450(a)(1).
  • Pursuant to the Nasdaq Listing Rules, the applicable grace period to regain compliance is 180 days, or until July 10, 2023.
  • The Company can cure this deficiency if the closing bid price of its ADSs is US$1.00 per share or higher for at least ten consecutive business days during the grace period.
  • The Company intends to cure the deficiency within the prescribed grace period.

Bilibili Inc. Announces Completion of Equity Offering

Retrieved on: 
Wednesday, January 11, 2023
Form, ADS, Security (finance), ADSS, HKEX, Goldman Sachs, Telephone, Sale, L.L.C, Prospectus

(“Goldman Sachs”) and its applicable affiliate(s), as duly engaged and authorized by the Company, from the holders of such Exchange Notes in privately negotiated transactions for the Company’s issuance of ADSs (the “Notes Purchase”) shortly thereafter.

Key Points: 
  • (“Goldman Sachs”) and its applicable affiliate(s), as duly engaged and authorized by the Company, from the holders of such Exchange Notes in privately negotiated transactions for the Company’s issuance of ADSs (the “Notes Purchase”) shortly thereafter.
  • The aggregate purchase price of the Exchange Notes in the amount of US$331.2 million will be funded by the net proceeds from the ADS Offering.
  • The ADS Offering has been made only by means of a prospectus supplement and an accompanying prospectus included in the Form F-3.
  • The registration statement on Form F-3 and the prospectus supplement are available at the SEC website at: http://www.sec.gov .

GDS Announces Private Placement of US$580 Million 4.50% Convertible Senior Notes Due 2030

Retrieved on: 
Wednesday, January 11, 2023
ADS, ADSS, Person, Risk, United, Sale, Acquisition, GDS, Security (finance), Note

The Notes will mature on January 31, 2030 (approximately the seventh anniversary of the issuance date).

Key Points: 
  • The Notes will mature on January 31, 2030 (approximately the seventh anniversary of the issuance date).
  • The conversion price represents a premium of approximately 16.7% to the volume weighted average price of GDS ADSs traded on NASDAQ for the 25 trading days immediately preceding the signing date.
  • J.P. Morgan acted as sole placement agent to GDS in connection with the private placement.
  • We may from time to time purchase our outstanding convertible notes through open market repurchases, privately negotiated transactions with individual holders or otherwise.